Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Oronsky

Showing results (31-40 of 115) with videos related to

Pageof 12
Sort By:
Frontiers in Oncology|June 14, 2023
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonistBryan Oronsky, Lori Takahashi, Richard Gordon, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2018
A note on improved statistical approaches to account for pseudoprogressionNacer Abrouk, Bryan Oronsky, Scott Caroen, et al.
Translational Oncology|November 13, 2014
Rewriting the epigenetic code for tumor resensitization: a reviewBryan Oronsky, Neil Oronsky, Jan Scicinski, et al.
Frontiers in Oncology|February 22, 2021
A Review of Newly Diagnosed GlioblastomaBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.
Theranostics|June 20, 2013
Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigmRamasamy Paulmurugan, Bryan Oronsky, Chad F Brouse, et al.
Case Reports in Oncology|June 15, 2017
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case ReportChristina Brzezniak, Bryan Oronsky, Corey A Carter, et al.
Biorheology|October 24, 2019
Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001Selma Cirrik, Elif Ugurel, Ali Cenk Aksu, et al.
Cancer Research|May 17, 2012
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materialsShoucheng Ning, Mark Bednarski, Bryan Oronsky, et al.
Pageof 12

Showing results (31-40 of 115) with videos related to

Sort By:
Pageof 12
Frontiers in Oncology|June 14, 2023
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonistBryan Oronsky, Lori Takahashi, Richard Gordon, et al.
Cancer Chemotherapy and Pharmacology|February 7, 2018
A note on improved statistical approaches to account for pseudoprogressionNacer Abrouk, Bryan Oronsky, Scott Caroen, et al.
Translational Oncology|November 13, 2014
Rewriting the epigenetic code for tumor resensitization: a reviewBryan Oronsky, Neil Oronsky, Jan Scicinski, et al.
Frontiers in Oncology|February 22, 2021
A Review of Newly Diagnosed GlioblastomaBryan Oronsky, Tony R Reid, Arnold Oronsky, et al.
Expert Opinion on Drug Delivery|April 26, 2020
Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mixScott Caroen, Bryan Oronsky, Corey Carter, et al.
Recent Patents on Biotechnology|January 13, 2023
Patent and Marketing Exclusivities 101 for Drug DevelopersBryan Oronsky, Scott Caroen, Franck Brinkhaus, et al.
Theranostics|June 20, 2013
Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigmRamasamy Paulmurugan, Bryan Oronsky, Chad F Brouse, et al.
Case Reports in Oncology|June 15, 2017
Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case ReportChristina Brzezniak, Bryan Oronsky, Corey A Carter, et al.
Biorheology|October 24, 2019
Nitrite may serve as a combination partner and a biomarker for the anti-cancer activity of RRx-001Selma Cirrik, Elif Ugurel, Ali Cenk Aksu, et al.
Cancer Research|May 17, 2012
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materialsShoucheng Ning, Mark Bednarski, Bryan Oronsky, et al.
Pageof 12